Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> reported modest revenue growth, gross margin contraction, and net profit decline in H1FY26, leading to ~30% correction in share price.</li>
<li>Cochlear expects stronger H2 and reiterated full-year guidance. As majority of Nexa contract renewals have been secured alongside modest price increases, the company is poised for accelerated growth ahead.</li>
<li>Cochlear shares are trading at NTM EV/EBITDA of 17.0x, well below five-years average. Cochlear can be a good defensive as well as value buying opportunity amid the U.S.-Iran war.</li>
</ul>



Cochlear Ltd (COH AU) reported modest revenue growth, gross margin contraction, and net profit decline in H1FY26, leading to ~30% correction in share price.
Cochlear expects stronger H2 and reiterated full-year guidance. As majority of Nexa contract renewals have been secured alongside modest price increases, the company is poised for accelerated growth ahead.
Cochlear shares are trading at NTM EV/EBITDA of 17.0x, well below five-years average. Cochlear can be a good defensive as well as value buying opportunity amid the U.S.-Iran war.


Cochlear Ltd (COH AU): Shares Pullback to COVID Lows; What’s Next?